190 related articles for article (PubMed ID: 36201716)
1.
Harriman JW; Espinel WF; Vagher J; Gammon A
JCO Precis Oncol; 2022 Oct; 6():e2100375. PubMed ID: 36201716
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
3. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
4. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
Witjes VM; Ligtenberg MJL; Vos JR; Braspenning JCC; Ausems MGEM; Mourits MJE; de Hullu JA; Adang EMM; Hoogerbrugge N
Gynecol Oncol; 2023 Jul; 174():121-128. PubMed ID: 37182432
[TBL] [Abstract][Full Text] [Related]
5. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
[TBL] [Abstract][Full Text] [Related]
6. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
[TBL] [Abstract][Full Text] [Related]
7. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract][Full Text] [Related]
8. Patients' attitudes regarding genetic counseling before germline BRCA1/2 pathogenic variants testing in Taiwan: A single-country, multi-center, patient-reported outcome study.
Kuo WL; Lin PH; Peng MT; Chu CH; Cho CW
J Genet Couns; 2023 Aug; 32(4):788-797. PubMed ID: 36872635
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
[TBL] [Abstract][Full Text] [Related]
10. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
11. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
13. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
15. Predicting the likelihood of a
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
[TBL] [Abstract][Full Text] [Related]
16. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
17. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
18. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
Sunar V; Korkmaz V; Topcu V; Cavdarli B; Arik Z; Ozdal B; Ustun YE
Asia Pac J Clin Oncol; 2022 Feb; 18(1):84-92. PubMed ID: 33629534
[TBL] [Abstract][Full Text] [Related]
19. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
[TBL] [Abstract][Full Text] [Related]
20.
Lanjouw L; Mourits MJE; Bart J; Ter Elst A; Berger LPV; van der Hout AH; Alam N; de Bock GH
Int J Gynecol Cancer; 2023 Aug; 33(8):1260-1269. PubMed ID: 37137525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]